Senators question Allergan CEO on tribe patent deal By: CNBC.com News November 07, 2017 at 15:11 PM EST A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis. Read More >> Related Stocks: Allergan Plc